Jean-Claude Tardif Selected Research

eicosapentaenoic acid ethyl ester

1/2022	Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCI.
1/2022	Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE-IT.
1/2022	Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment.
1/2022	Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction.
12/2021	Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG.
11/2021	Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL.
10/2021	Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT.
1/2021	Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses.
1/2020	REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States.
11/2019	Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jean-Claude Tardif Research Topics

Disease

62	Coronary Artery Disease (Coronary Atherosclerosis) 08/2022 - 01/2002
58	Myocardial Infarction 01/2022 - 01/2002
54	Atherosclerosis 08/2022 - 01/2002
53	Heart Failure 10/2022 - 05/2002
43	Inflammation (Inflammations) 01/2022 - 01/2002
41	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 04/2004
35	Acute Coronary Syndrome 01/2022 - 03/2003
30	Atrial Fibrillation 01/2022 - 05/2002
27	Stroke (Strokes) 01/2022 - 03/2004
24	Atherosclerotic Plaque (Atheroma) 11/2021 - 11/2004
21	Fibrosis (Cirrhosis) 09/2021 - 06/2003
20	Left Ventricular Dysfunction 01/2021 - 02/2003
18	Type 2 Diabetes Mellitus (MODY) 01/2022 - 08/2011
16	Coronary Disease (Coronary Heart Disease) 01/2021 - 04/2006
14	Hypertension (High Blood Pressure) 01/2022 - 07/2004
11	Pulmonary Hypertension 03/2021 - 03/2004
10	Aortic Valve Stenosis (Aortic Stenosis) 01/2021 - 02/2014
9	COVID-19 03/2022 - 01/2021
9	Hemorrhage 12/2021 - 05/2008
9	Disease Progression 11/2019 - 01/2002
9	Stable Angina 09/2013 - 12/2005
7	Hypertriglyceridemia 01/2022 - 06/2008
7	Vascular Diseases (Vascular Disease) 09/2021 - 02/2003
7	Pathologic Constriction (Stenosis) 12/2020 - 12/2005
7	ST Elevation Myocardial Infarction 11/2020 - 10/2010
6	Infarction (Infarctions) 01/2022 - 12/2007
6	Heart Diseases (Heart Disease) 01/2022 - 07/2004
6	Unstable Angina 11/2021 - 01/2005
6	Infections 10/2021 - 01/2005
6	Cardiac Arrhythmias (Arrythmia) 11/2020 - 07/2004
6	Diabetes Mellitus 01/2020 - 03/2007
6	Dyslipidemias (Dyslipidemia) 01/2018 - 01/2010
6	Myocardial Ischemia (Ischemic Heart Diseases) 10/2017 - 01/2006
6	Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left) 09/2012 - 08/2003
5	Hypertrophy 01/2022 - 07/2016
5	Gout 01/2022 - 01/2013
5	Carotid Artery Diseases 01/2021 - 02/2003
5	Hypercholesterolemia 12/2019 - 01/2012
5	Cardiomyopathies (Cardiomyopathy) 12/2019 - 07/2006
5	Obesity 07/2019 - 08/2015
5	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 07/2018 - 01/2012
5	Metabolic Syndrome (Dysmetabolic Syndrome X) 04/2011 - 02/2006
4	Pericarditis 01/2022 - 12/2019
4	Insulin Resistance 03/2021 - 08/2011
4	Heart Arrest (Cardiac Arrest) 01/2021 - 11/2012
4	Systolic Heart Failure 12/2019 - 08/2013

Drug/Important Bio-Agent (IBA)

37	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2022 - 10/2002
27	LipidsIBA 12/2021 - 01/2005
24	IvabradineIBA 01/2020 - 12/2005
22	Colchicine FDA LinkGeneric 03/2022 - 12/2019
21	Biomarkers (Surrogate Marker)IBA 08/2022 - 06/2006
18	CholesterolIBA 08/2022 - 01/2005
15	Proteins (Proteins, Gene)FDA Link 01/2022 - 07/2006
15	LDL CholesterolIBA 12/2021 - 05/2008
14	Pharmaceutical PreparationsIBA 10/2022 - 06/2008
14	HDL LipoproteinsIBA 01/2021 - 08/2006
13	HDL CholesterolIBA 01/2020 - 02/2006
13	AntioxidantsIBA 05/2008 - 01/2002
12	dalcetrapibIBA 06/2021 - 12/2009
11	C-Reactive ProteinIBA 08/2022 - 04/2003
11	eicosapentaenoic acid ethyl esterIBA 01/2022 - 01/2019
11	Glucose (Dextrose)FDA LinkGeneric 01/2017 - 03/2007
10	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 10/2022 - 05/2002
10	oxidized low density lipoproteinIBA 08/2022 - 01/2005
9	succinobucol (AGI 1067)IBA 05/2008 - 01/2002
8	Triglycerides (Triacylglycerol)IBA 01/2022 - 03/2009
8	Apolipoprotein A-I (Apolipoprotein A1)IBA 01/2021 - 06/2008
8	Atorvastatin (Lipitor)FDA Link 04/2014 - 01/2005
8	Probucol (Lorelco)FDA Link 05/2006 - 01/2002
7	Biological ProductsIBA 01/2022 - 01/2016
7	Natriuretic PeptidesIBA 01/2022 - 05/2009
7	Lipoproteins (Lipoprotein)IBA 01/2022 - 01/2008
7	Cholesterol Ester Transfer ProteinsIBA 01/2020 - 12/2008
7	CollagenIBA 01/2020 - 01/2002
7	Phenobarbital (Luminal)FDA Link 05/2008 - 01/2002
6	CalciumIBA 08/2022 - 04/2008
6	lixisenatideIBA 01/2022 - 05/2015
6	pro-brain natriuretic peptide (1-76)IBA 01/2022 - 09/2014
6	aleglitazarIBA 01/2018 - 09/2013
6	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 06/2007 - 05/2002
5	Interleukin-6 (Interleukin 6)IBA 08/2022 - 01/2013
5	Lipoprotein(a)IBA 08/2022 - 06/2014
5	ApolipoproteinsIBA 01/2018 - 02/2003
5	Enalapril FDA LinkGeneric 10/2006 - 05/2002
4	Messenger RNA (mRNA)IBA 01/2022 - 05/2009
4	Anti-Inflammatory Agents (Anti-Inflammatories)IBA 01/2022 - 12/2007
4	InterleukinsIBA 11/2021 - 01/2013
4	AnticoagulantsIBA 01/2021 - 01/2015
4	Warfarin (Coumadin)FDA LinkGeneric 01/2021 - 11/2005
4	bococizumabIBA 07/2018 - 08/2016
4	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2017 - 05/2009
4	P-SelectinIBA 11/2016 - 11/2012

Therapy/Procedure

87	Therapeutics 01/2022 - 01/2002
16	Percutaneous Coronary Intervention 01/2022 - 01/2002
10	Coronary Artery Bypass (Coronary Artery Bypass Surgery) 10/2017 - 05/2006
8	Secondary Prevention 01/2022 - 07/2006
5	Stents 11/2021 - 01/2002
5	Cardiopulmonary Bypass (Heart-Lung Bypass) 10/2016 - 10/2006
5	Catheters 10/2015 - 03/2004
4	Drug Therapy (Chemotherapy) 12/2019 - 02/2005